Search

Your search keyword '"Taleghani, Mohammad"' showing total 3 results
3 results on '"Taleghani, Mohammad"'

1. Polymorphism of SMAD7 gene (rs2337104) and risk of colorectal cancer in an Iranian population: a case-control study.

Author

Akbari, Zahra, Safari-Alighiarloo, Nahid, Taleghani, Mohammad Yaghoob, Mirfakhar, Farzaneh Sadat, Aghdaei, Hamid Asadzadeh, Vahedi, Mohsen, Shemirani, Atena Irani, Nazemalhosseini-Mojarad, Ehsan, and Zali, Mohammad Reza

Subjects
*LIVER disease diagnosis, *SMOKING, *ACADEMIC medical centers, *CANCER patients, *CHI-squared test, *CONFIDENCE intervals, *COLON tumors, *REPORTING of diseases, *GASTROENTEROLOGY, *GENES, *GENETIC polymorphisms, *GENETICS, *GROWTH factors, *MEDICAL ethics, *NOSOLOGY, *POPULATION, *T-test (Statistics), *TUMOR classification, *DATA analysis, *CONTROL groups, *CASE-control method, *DATA analysis software, *ODDS ratio, *GENOTYPES, *DIAGNOSIS, *TUMOR risk factors, *CANCER risk factors, RECTUM tumors
Abstract

Aim: The purpose of this study was to evaluate the influence of intronic polymorphism of the SMAD7 (Mothers Against Decantaplegic Homolog 7) gene (rs2337104) on the risk of colorectal cancer (CRC) and clinicopathological features in an Iranian population. Background: SMAD7 has been identified as an antagonist of transforming growth factor beta (TGF-b)-mediating fibrosis, carcinogenesis, and inflammation. Regarding to the recent genome-wide scan, a risk locus for colorectal cancer at 18q21 has been found, which maps to the SMAD7 gene. Patients and methods: This case-control study was performed on 109 CRC patients and 109 healthy controls recruited in Taleghani Hospital. The genotyping of all samples were done by TaqMan assay via an ABI 7500 Real Time PCR System (Applied Biosystems) with DNA from peripheral blood. The association of this polymorphism with the risk of CRC and clinicopathological features was investigated. Results: Our results indicated that there were no significant association between genotypic and allelic frequencies of SMAD7 polymorphism (rs2337104) and CRC risk in our population. Although the T allele is the most frequent one in this population and its frequency was 86.7% in patients compared with 91.7% in controls (OR=1.705, 95% CI= 0.916-3.172). Also, the SMAD7 genotypes were not associated with any clinicopathological characteristics in CRC patients (P>0.05). Conclusion: For the first time, this study results revealed that this SMAD7 polymorphism couldn't be a potential risk factor for CRC or a prognostic biomarker for prediction of clinicopathological features in an Iranian population. A largescale case-control study is needed to validate our results. [ABSTRACT FROM AUTHOR]

Published
2014

2. Prevalence and prognostic role of PIK3CA E545K mutation in Iranian colorectal cancer patients.

Author

Ranjbar, Reza, Mohammadpour, Somayeh, Esfahani, Amir Torshizi, Namazian, Sina, Yaghob-Taleghani, Mohammad, Baghaei, Kaveh, Tabatabaei, Seyed Abdolreza Mortazavi, Pasharavesh, Leila, and Nazemalhosseini-Mojarad, Ehsan

Subjects
*FORMALDEHYDE analysis, *COLON tumors, *CONFIDENCE intervals, *MULTIVARIATE analysis, *GENETIC mutation, *PHOSPHOTRANSFERASES, *POLYMERASE chain reaction, *SURVIVAL analysis (Biometry), *SYMPTOMS, *DISEASE prevalence, *RETROSPECTIVE studies, *DISEASE progression, *KAPLAN-Meier estimator, *SEQUENCE analysis, *ODDS ratio, RECTUM tumors
Abstract

Aim: This study aimed to evaluate the distribution of PIK3CA E545K mutation in Iranian CRC patients and explored its roles in disease prognosis. Background: Deregulation of the phosphoinositide 3-kinase (PI3K) pathway contributes to the progression of tumors. The p110a (PIK3CA), a catalytic subunit of PIK3, is mutated in many types of cancers. Exon 9 (E545K) is the most frequently mutated hotspot in PIK3CA in colorectal cancer (CRC). However, the prognostic role of PIK3CA E545K mutation needs to be elucidated. Methods: Tumors from 187 CRC patients were retrospectively collected from the Taleghani and Shohada Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, between 2010 and 2017. PIK3CA E545K status was detected in Formalin-fixed paraffin-embedded (FFPE) tissues using PCR-RFLP methods, and validated by pyrosequencing. Correlations between PIK3CA E545K mutation clinicopathological features were analyzed. Results: The frequency of PIK3CA E545K gene mutations in CRC patients was 10.7%. Significant correlations were observed in PIK3CA E545K mutation with tumor differentiation and TNM stage (p < 0.042 and p = 0.033, respectively). Kaplan-Meier analysis showed a worse prognosis in overall survival (OS) in patients with PIK3CA E545K mutation (p < 0.001). Multivariate analysis indicated that PIK3CA E545K mutation was a detrimental factor for OS (HR = 6.497, 95% CI: 2.859-14.768, p < 0.021). Conclusion: A high frequency of PIK3CA E545K mutation was detected in Iranian CRC patients. The results of the present study suggested that PIK3CA E545K mutation may be associated with poor prognosis. These findings require further confirmation via prospective studies with larger samples. [ABSTRACT FROM AUTHOR]

Published
2019

3. Lack of BRAFV600E mutation in stage I and II of colorectal cancer.

Author

Molaei, Mahsa, Farahani, Roya Kishani, Maftouh, Mina, Taleghani, Mohammad Yaghoob, Vahdatinia, Mahsa, Khatami, Fatemeh, Nazemalhosseini-Mojarad, Ehsan, Aghdae, Hamid Asadzadeh, Aboutorabi, Akram, and Zali, Mohammad Reza

Subjects
*SMOKING, *BIOCHEMISTRY, *CANCER patients, *CHI-squared test, *COLON tumors, *STATISTICAL correlation, *DEMOGRAPHY, *ALCOHOL drinking, *DRUG resistance, *FISHER exact test, *GASTROENTEROLOGY, *GENES, *GENETIC mutation, *POLYMERASE chain reaction, *PROTEIN kinases, *T-test (Statistics), *TUMOR classification, *DNA-binding proteins, *DATA analysis, *HUMAN research subjects, *CROSS-sectional method, *RETROSPECTIVE studies, *PATIENT selection, *DATA analysis software, *SEQUENCE analysis, *MANN Whitney U Test, *TUMOR grading, *DIAGNOSIS, RECTUM tumors
Abstract

Aim: We aimed to explore the frequency of BRAFV600E mutation in Iranian patients with colorectal cancer (CRC) as well as its association with clinic pathological characteristic of patients. Background: CRC is the third leading cause of cancer related death. There is a growing body of data showing the association of BRAFV600E mutation with malignant transformation and clinical outcome of different tumors, including CRC. These findings suggest that BRAFV600E mutation can be used as diagnostic and/or prognostic biomarker for management of cancer patients. Patients and methods: A total of 85 patients with sporadic tumor were recruited. BRAFV600E mutation was investigated using sequencing of extracted DNAs from formalin-fixed paraffin-embedded (FFPE) tumor tissues. Electropherograms were analyzed using Laser-gene 6 software. Results: More than 95% of patients were in stage I and II and none of them were in stage IV. Patients were mostly below 55 years old and tumors were dominantly located in the distal colon. Of note, no BRAFV600E mutations were detected in our population. Conclusion: Our results showed no V600E mutation in the BRAF gene in stage I and II of CRC patients. Further studies in multi-center settings are warranted to examine the prognostic and/or predictive value of this marker in different stages of colorectal cancer patients. [ABSTRACT FROM AUTHOR]

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results